BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 7528032)

  • 1. Ovarian ablation as treatment for young women with breast cancer.
    Davidson NE
    J Natl Cancer Inst Monogr; 1994; (16):95-9. PubMed ID: 7528032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is the role of ovarian ablation in the management of primary and metastatic breast cancer today?
    Prowell TM; Davidson NE
    Oncologist; 2004; 9(5):507-17. PubMed ID: 15477635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
    El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
    Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The use of GnRH analogues in early and advanced breast carcinomas].
    Ségura C; Avenin D; Gligorov J; Selle F; Estéso A; Beerblock K; Emile G; Do Huyen N; Lotz JP
    Gynecol Obstet Fertil; 2005 Nov; 33(11):914-9. PubMed ID: 16246613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial.
    Adjuvant Breast Cancer Trials Collaborative Group
    J Natl Cancer Inst; 2007 Apr; 99(7):516-25. PubMed ID: 17405996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
    Tan SH; Wolff AC
    Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian ablation as adjuvant therapy for early-stage breast cancer.
    Pritchard KI
    Cancer Treat Res; 1998; 94():158-80. PubMed ID: 9587687
    [No Abstract]   [Full Text] [Related]  

  • 8. Ovarian ablation as a treatment for breast cancer.
    Sainsbury R
    Surg Oncol; 2003 Dec; 12(4):241-50. PubMed ID: 14998564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer.
    Ejlertsen B; Mouridsen HT; Jensen MB; Bengtsson NO; Bergh J; Cold S; Edlund P; Ewertz M; de Graaf PW; Kamby C; Nielsen DL
    J Clin Oncol; 2006 Nov; 24(31):4956-62. PubMed ID: 17075113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is it time to develop an optimal endocrine therapy for premenopausal patients with axillary node positive and negative breast cancer?
    Bilimoria MM; Jordan VC
    Semin Surg Oncol; 1996; 12(5):339-45. PubMed ID: 8873322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant therapy for premenopausal patients with early breast cancer.
    Kurebayashi J
    Curr Opin Obstet Gynecol; 2008 Feb; 20(1):51-4. PubMed ID: 18197006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian ablation in the adjuvant treatment of premenopausal and perimenopausal breast cancer.
    Sainsbury R
    Br J Surg; 2003 May; 90(5):517-26. PubMed ID: 12734855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant hormonal therapy for premenopausal women with breast cancer.
    Emens LA; Davidson NE
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):486S-94S. PubMed ID: 12538505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant ovarian suppression versus chemotherapy for premenopausal, hormone-responsive breast cancer: quality of life and efficacy tradeoffs.
    Elkin EB; Weinstein MC; Kuntz KM; Bunnell CA; Weeks JC
    Breast Cancer Res Treat; 2005 Sep; 93(1):25-34. PubMed ID: 16184455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma.
    Recchia F; Saggio G; Amiconi G; Di Blasio A; Cesta A; Candeloro G; Rea S
    Cancer; 2006 Feb; 106(3):514-23. PubMed ID: 16388519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian suppression in the management of premenopausal breast cancer: methods and efficacy in adjuvant and metastatic settings.
    McDonald Wade S; Hackney MH; Khatcheressian J; Lyckholm LJ
    Oncology; 2008; 75(3-4):192-202. PubMed ID: 18841034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of ovarian ablation in the management of breast cancer.
    Wirk B
    Breast J; 2005; 11(6):416-24. PubMed ID: 16297086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.
    Sverrisdóttir A; Fornander T; Jacobsson H; von Schoultz E; Rutqvist LE
    J Clin Oncol; 2004 Sep; 22(18):3694-9. PubMed ID: 15365065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women.
    Love RR; Van Dinh N; Quy TT; Linh ND; Tung ND; Shen TZ; Hade EM; Young GS; Jarjoura D
    J Clin Oncol; 2008 Jan; 26(2):253-7. PubMed ID: 18086800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormonal approaches to breast cancer treatment and prevention: an overview.
    Vogel CL
    Semin Oncol; 1996 Aug; 23(4 Suppl 9):2-9. PubMed ID: 8824459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.